Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: Pasco Hernando Oncology Associates, PA, New Port Richey, Florida
Conditions: Carcinoma, Squamous Cell of the Head and Neck
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Lakeland, Florida +3 locations
Conditions: Carcinoma, Non-Small Cell Lung
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Tampa, Florida
Conditions: Melanoma
Combination Chemotherapy in Treating Children With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: Broward General Medical Center Cancer Center, Fort Lauderdale, Florida +13 locations
Conditions: Neuroblastoma
Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/23/2014
Locations: Broward General Medical Center, Fort Lauderdale, Florida +13 locations
Conditions: Kidney Cancer
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
Completed
This is a clinical research study to evaluate if chemotherapy in the experimental arm (E) results in a better outcome compared to patients in the standard of care arm (C). 2:1 randomization to experimental arm (E) or standard arm (C). In arm E, treatment of dual-agent chemotherapy will be selected based on RRM1 and ERCC1 expression at the protein level. In arm C, treatment of dual-agent chemotherapy will be gemcitabine/carboplatin, i.e., standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2014
Locations: Center for Cancer Care & Research/Watson, Lakeland, Florida +2 locations
Conditions: Non-Small Cell Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
Terminated
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2014
Locations: Halifax Medical Center - Daytona Beach, Daytona Beach, Florida +1 locations
Conditions: Lung Cancer
Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy followed by adenovirus p53 vaccine therapy in treating patients who have extensive-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2014
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lung Cancer
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Completed
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2014
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida +1 locations
Conditions: Head and Neck Neoplasms
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurren... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/12/2014
Locations: H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Completed
Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2014
Locations: Florida Cancer Specialists, Fort Myers, Florida
Conditions: Metastatic Melanoma
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
Completed
The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2013
Locations: H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida
Conditions: Advanced Melanoma